Evidence map›Paper›PMID 40271095›Full record

ReviewClinical hematology international2025

Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.

Wenming Chen, Zhen Cai, James Cs Chim, Wee Joo Chng, Juan Du, Chengcheng Fu, Ichiro Hanamura, Jian Hou, Jeffrey Shang-Yi Huang, Tadao Ishida and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical hematology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wenming ChenDepartment of Hematology, Myeloma Research Center of Beijing Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Zhen CaiSchool of Medicine First Affiliated Hospital Zhejiang University, China.
James Cs ChimUniversity of Hong Kong, Hong Kong.
Wee Joo ChngNational University Cancer Institute, Singapore.
Juan DuMyeloma & Lymphoma Center Shanghai Changzheng Hospital, China.
Chengcheng FuFirst Affiliated Hospital of Soochow University, China.
Ichiro HanamuraDivision of Hematology, Department of Internal Medicine Aichi Medical University, Japan.
Jian HouDepartment of Hematology Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China.
Jeffrey Shang-Yi HuangNational Taiwan University Hospital, Taiwan.
Tadao IshidaJapanese Red Cross Medical Center, Japan.
Aijun LiuDepartment of Hematology, Myeloma Research Center of Beijing Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Vadim PtushkinBotkin Moscow City Clinical Hospital, Russia.
Anastasiya SemenovaRussian Cancer Research Center named after N.N. Blokhin RAMS, Russia.
Naoki TakezakoNerima Hikarigaoka Hospital, Japan.
Raymond Siu Ming WongSir Y.K. Pao Centre for Cancer & Department of Medicine and Therapeutics Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic outcomes of clinical trials for incorporating anti-CD38 monoclonal antibodies (including isatuximab and daratumumab) into the bortezomib/lenalidomide/dexamethasone (VRd) triplet therapy backbone as the first-line treatment for newly diagnosed multiple myeloma (NDMM) have demonstrated significant improved efficacies. From a safety perspective, the addition of anti-CD38 monoclonal antibodies into the triplet therapies did not raise additional safety concerns. Based on the promising results, the National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 had updated the quadruplet therapy incorporating anti-CD38 monoclonal antibodies with VRd-based therapies as the primary therapy for both transplantation-eligible and transplantation-ineligible NDMM patients. Thus, a panel of experts in hematology and oncology with extensive experience in the treatment of NDMM was convened in 2024 to develop consensus recommendations based on recent evidence from pivotal clinical trials and real-world practices, providing clear guidance for optimizing treatment strategies in both transplantation-eligible and transplantation-ineligible patients. The main topics identified for discussion and recommendation were: (i) the benefits and indications for quadruplet therapy for NDMM; (ii) the optimization of quadruplet therapy strategies; (iii) the management and monitoring of potential adverse events for quadruplet therapy, and (iv) the impact of quadruplet regimens on tandem stem cell transplantation and maintenance treatment. Recommendations were then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.

Indexed as

Anti-CD38 monoclonal antibodyDaratumumabIsatuximabMultiple myelomaNewly diagnosedQuadruplet therapy

Identifiers

PMID40271095
PMCPMC12013828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.